In 2025, flexibility is our goal
You spoke and we listened! In 2025, we will be piloting changes to our scheme portfolio to enable more flexibility when participating in EQA. New for 2025, the hereditary hearing loss scheme has options to participate in EQA for either targeted DFNB1 locus testing, or for gene panel testing, enabling you to choose the […]
The new 2025 catalogue is coming soon… with some big changes!
You spoke and we listened! We are updating our catalogue and some of our EQA schemes based on your feedback to better meet the needs of laboratories. We have reduced the maximum number of molecular pathology cases from ten to five, to save analysis costs and time. We are increasing the number of schemes for […]
Webinar: Rapid Point-of-Care Testing: The Next Frontier in Pharmacogenomics by John McDermott
Dr John McDermott is a Clinical Geneticist and an NIHR Doctoral Research Fellow at the University of Manchester. He was the UK’s first Academic Clinical Fellow in Genomic Medicine. Working at the Manchester Centre for Genomic Medicine his research focuses on the application of genomics in acute and everyday healthcare settings. He has recently been […]
Enhancing Point-of-Care Testing (POCT): EMQN CIC to introduce innovative EQA Scheme for MT-RNR1 m.1555A>G POCT
As the healthcare landscape has begun to rely increasingly on the use of point-of-care testing at, or close to, the patient’s bedside, it is crucial to ensure those tests are accurate and reliable, since immediate clinical decisions are based on the outcomes where even the slightest error could have profound consequences. EMQN CIC has introduced […]
EMQN CIC and SensID GmbH announce new External Quality Assessment (EQA) / Proficiency Testing (PT) scheme for circulating tumour DNA extraction from plasma
EMQN CIC and SensID GmbH are pleased to announce a strategic partnership to deliver a new External Quality Assessment (EQA) / Proficiency Testing (PT) scheme for circulating tumour DNA (ctDNA) extraction from plasma. Background The use of molecular testing to aid in determining therapy options for the treatment of non-small cell lung cancer (NSCLC) is now […]
Introducing the new look EMQN strategy and brand
To consolidate our position as the leading global provider of quality assurance services and knowledge to the human molecular pathology and genetics testing community, we have refined our strategy and launched a distinctive new brand and website. Our aim with this is to better reach new laboratories that could benefit from our help, to help […]
